Anti-inflammatory drug reduces key complication risk in HIV-positive TB patients
Trial finds that prednisone can reduce the risk of TB-IRIS – a serious complication seen in HIV-positive tuberculosis (TB) patients.
Killer immune cells fend off viruses with a helping hand from key proteins
New research reveals how killer cell immunoglobin-like receptors (KIRs) can strengthen the immune system’s response to HIV-1, HCV and HTLV-1 infection
Imperial diabetes researcher named as one of London’s leading health influencers
Dr Shivani Misra has been featured as part of the Evening Standard’s annual Progress 1000 list of influential Londoners.
Gatekeeping protein could be key target for controlling severe asthma
New study highlights how ABIN-2’s role in regulating allergic airway inflammation could make it a potential target for treating asthma.
Imperial immunologist recognised by World Economic Forum
Dr Julia Makinde was selected to join a cohort of outstanding young scientists at the World Economic Forum’s Annual Meeting of the New Champions.
Potential tuberculosis vaccine shows early promise in clinical trial
Ongoing clinical trial yields positive preliminary results for candidate tuberculosis (TB) vaccine M72/AS01E1.
Childhood TB burden could be reduced by better targeting of high-risk households
Study reveals untapped potential of household contact management strategies as UN General Assembly gathers for first-ever high-level meeting on TB.
Feature
What happens when our cells stop cleaning up after themselves?
A cell needs to get rid of its waste proteins effectively in order to function – but what happens to our bodily tissue when this system breaks down?
CD153: the molecule with potential protective power against TB infection
A study published this week in Nature Microbiology identifies the molecule CD153 as potentially key to controlling tuberculosis (TB) infection.
Big data approach to drug discovery leads to new epilepsy target
A newly-developed computational framework for drug discovery has been used to identify a therapeutic target for epilepsy.
